KRAS and neoplasm: In subgroup analyses of EGFR‐ and KRAS‐mutated cases, there was no significant difference in survival between tumours with and without expression of NKX2‐1/TTF‐1 exon 1, although the latter had shorter OS (41 months in EGFR‐mutated cases and 36 months in KRAS‐mutated cases) (see supplementary material, Figure S3).